+44 20 8123 2220
info@marketpublishers.com

Hepatitis C [2016]: Bulletin #3

https://marketpublishers.com/r/H7CDC22449EEN.html
Date: May 2017
Pages: 0
Price: US$ 1,045.00 (Single User License)
ID: H7CDC22449EEN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating an update on the results of its triple combination JNJ-4178 (simeprevir/odalasvir/AL-335) in an ongoing Phase II study; AbbVie announcing positive data from two Phase III studies, ENDURANCE-3 and EXPEDITION-1, with its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Merck & Co. announcing positive results from the Phase II C-SURGE study in which MK-3682B, its triple-combination of uprifosbuvir, grazoprevir and rusazvir, which is being investigated in treatment-experienced GT1 patients for whom treatment with approved direct-acting antiviral (DAA) regimens has previously failed.

Business Questions

Are KOLs impressed by JNJ-4178’s efficacy in treatment-naïve, GT1, non-cirrhotic HCV patients?

Will JNJ-4178’s 6-week treatment duration provide it with a competitive edge over competing 8-week HCV regimens?

Do KOLs think that JNJ-4178 will prove to be effective in other HCV genotypes?

Could the increasing availability of pan-genotypic HCV therapies limit JNJ-4178’s success?

How do KOLs view G/P’s pan-genotypic performance in the EXPEDITION-1 and ENDURANCE-3 studies?

Do KOLs expect G/P to satisfy any unmet therapeutic needs within the HCV

+44 20 8123 2220
info@marketpublishers.com

market, such as for GT3 infected or renally-insufficient patients?

What role will pricing and marketing play in terms of helping G/P to establish a position within the HCV treatment paradigm?

How do KOLs rate MK-3682B's response rates for treatment-experienced GT1 patients in the Phase II C-SURGE study?

Is MK-3682B destined to become a salvage therapy for DAA-experienced HCV patients?

How large is the patient pool for MK-3682B likely to be given the high success rates achieved by DAA regimens for treating HCV?

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Hepatitis C [2016]: Bulletin #3
Product link: https://marketpublishers.com/r/H7CDC22449EEN.html
Price: US$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H7CDC22449EEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970